| 101 | 9806544 | PML induces a novel caspase-independent death process. | Nat Genet | 1998 Nov |
3 |
| 102 | 9834237 | Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. | Blood | 1998 Dec 1 |
5 |
| 103 | 9885291 | SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. | J Cell Sci | 1999 Feb |
2 |
| 104 | 9891864 | The molecular biology of acute promyelocytic leukemia. | Cancer Treat Res | 1999 |
2 |
| 105 | 10023669 | Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. | Oncogene | 1999 Jan 28 |
1 |
| 106 | 10023688 | Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. | Oncogene | 1999 Jan 28 |
1 |
| 107 | 10029573 | Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. | Blood | 1999 Mar 1 |
5 |
| 108 | 10075924 | Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. | EMBO J | 1999 Mar 15 |
1 |
| 109 | 10077561 | Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. | Proc Natl Acad Sci U S A | 1999 Mar 16 |
1 |
| 110 | 10203615 | Efficacy of all-trans retinoic acid for molecular relapse of acute promyelocytic leukemia during remission. | Oncol Rep | 1999 May-Jun |
3 |
| 111 | 10233384 | Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party. | Br J Haematol | 1999 Apr |
1 |
| 112 | 10328107 | Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. | J Natl Cancer Inst | 1999 May 5 |
2 |
| 113 | 10330422 | CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. | J Clin Invest | 1999 May 15 |
1 |
| 114 | 10356361 | Transcriptional activation of the cyclin-dependent kinase inhibitor p21 by PML/RARalpha. | Mol Cell Biol Res Commun | 1999 May |
2 |
| 115 | 10359529 | A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. | Oncogene | 1999 May 27 |
2 |
| 116 | 10373566 | PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. | Mol Cell Biol | 1999 Jul |
10 |
| 117 | 10374879 | In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. | Leukemia | 1999 May |
7 |
| 118 | 10439807 | A rapid practical RT-PCR-based approach for the detection of the PML/RAR alpha fusion transcript in acute promyelocytic leukemia. | Am J Clin Pathol | 1999 Aug |
1 |
| 119 | 10504293 | A dynamic connection between centromeres and ND10 proteins. | J Cell Sci | 1999 Oct |
1 |
| 120 | 10539879 | All trans-retinoic acid decreases early mortality in patients with promyelocytic leukemia and can be given entirely on an outpatient basis. | Am J Hematol | 1999 Nov |
1 |
| 121 | 10553155 | Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. | Haematologica | 1999 Nov |
4 |
| 122 | 10556184 | A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. | Blood | 1999 Nov 1 |
3 |
| 123 | 10597230 | Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response. | Oncogene | 1999 Nov 4 |
5 |
| 124 | 10597310 | The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control. | Oncogene | 1999 Nov 25 |
1 |
| 125 | 10610177 | A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. | Nat Genet | 1999 Nov |
3 |
| 126 | 10611294 | Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. | Proc Natl Acad Sci U S A | 1999 Dec 21 |
6 |
| 127 | 10620019 | Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. | Genes Cells | 1999 Dec |
3 |
| 128 | 10637480 | The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia. | Leukemia | 2000 Jan |
2 |
| 129 | 10673742 | A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML/RARA transcriptional activities. | Leukemia | 2000 Feb |
5 |
| 130 | 10684855 | Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. | J Exp Med | 2000 Feb 21 |
2 |
| 131 | 10702898 | Acute promyelocytic leukemia. From morphology to molecular lesions. | Clin Lab Med | 2000 Mar |
1 |
| 132 | 10766166 | Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. | Cancer Res | 2000 Apr 1 |
3 |
| 133 | 10770516 | Homocysteine concentrations and methionine loading in patients on antiepileptic drugs. | Acta Neurol Scand | 2000 Apr |
9 |
| 134 | 10784426 | Two flavonoids from the leaves of Morus alba induce differentiation of the human promyelocytic leukemia (HL-60) cell line. | Biol Pharm Bull | 2000 Apr |
2 |
| 135 | 10830735 | Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. | Leuk Lymphoma | 2000 Jul |
2 |
| 136 | 10865965 | Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. | Leukemia | 2000 Jun |
1 |
| 137 | 10870476 | Current issues in the management of acute promyelocytic leukemia. | Ann Hematol | 2000 May |
3 |
| 138 | 10874212 | Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. | Jpn J Cancer Res | 2000 Jun |
3 |
| 139 | 10901625 | Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism. | Amino Acids | 2000 |
3 |
| 140 | 10910048 | BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. | Cancer Res | 2000 Jul 1 |
2 |
| 141 | 10942370 | A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. | Blood | 2000 Aug 15 |
1 |
| 142 | 10950866 | PML is induced by oncogenic ras and promotes premature senescence. | Genes Dev | 2000 Aug 15 |
1 |
| 143 | 11007958 | The promyelocytic (PML) nuclear compartment and transcription control. | Biochem Pharmacol | 2000 Oct 15 |
1 |
| 144 | 11050004 | Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. | Blood | 2000 Nov 1 |
3 |
| 145 | 11112687 | Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies. | J Cell Sci | 2001 Jan |
2 |
| 146 | 11133770 | Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. | Blood | 2001 Jan 1 |
4 |
| 147 | 11158586 | Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. | Proc Natl Acad Sci U S A | 2001 Jan 30 |
2 |
| 148 | 11161273 | Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5. | J Gen Virol | 2001 Feb |
1 |
| 149 | 11172537 | Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. | Semin Hematol | 2001 Jan |
3 |
| 150 | 11259576 | The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. | Mol Cell Biol | 2001 Apr |
1 |